Phibro Animal Health Corporation (PAHC) AI Stock Analysis

Headquartered in Teaneck, New Jersey, Phibro Animal Health Corporation develops, manufactures, and supplies animal health and mineral nutrition products catering to both food and companion animals. Operating across three segments Animal Health, Mineral Nutrition, and Performance Products the company serves poultry, swine, beef and dairy cattle, aquaculture species, and dogs. Its animal health portfolio features antibacterials, anticoccidials, anthelmintics, and anti-bloat treatments for cattle. In addition, Phibro produces specialty nutritional products and formulations of trace minerals such as zinc, manganese, copper, and iron, which also serve personal care, industrial chemicals, and chemical catalysts. Products are distributed globally through local sales offices.

Phibro expanded revenue from $942.3M in FY2022 to $1.02B in FY2024, before accelerating to $1.30B in FY2025 and $1.52B in FY2026, achieving a 5-year revenue CAGR of 12.7%. Gross margin widened from 30.3% in FY2022 to 33.7% in FY2026, while operating margin expanded to 13.1% from 8.4% in FY2022. Net income increased from $49.2M in FY2022 to $99.7M in FY2026, with EPS rising from $1.31 to $3.21. For the latest quarter ended June 30, 2026, quarterly revenue grew 4.8% year-over-year, and quarterly earnings grew 24.6% year-over-year, supported by a trailing twelve months net profit margin of 6.6%.

As of June 30, 2026, Phibro held $82.0M in cash and short-term investments against $788.8M in total debt, resulting in net debt of $706.8M and a debt-to-equity ratio of 2.05. Shareholders' equity stood at $385.5M, supported by a current ratio of 2.96. Operating cash flow reached $69.0M in FY2026, down from $80.1M in FY2025, yielding free cash flow of $9.9M after capital expenditures of $59.1M. Cash distributions included $19.5M in dividends paid during FY2026, while share count changed by 1.2% over 5 years.

PAHC trades at a trailing P/E of 16.0x and a forward P/E of 13.8x, both below the median of its US-listed Healthcare peers at 24.6x and 17.3x, respectively. Its enterprise value to EBITDA ratio is 9.0x compared to the peer median of 12.0x, and its price-to-sales multiple is 1.0x against the peer median of 4.1x. Over the past year, PAHC shares gained 1.9%, trailing the S&P 500 (SPY) return of 16.8%. Over five years, however, PAHC returned 101.8%, outperforming the S&P 500 (SPY) return of 83.0%.

PAHC pays a forward annual dividend of $0.48 per share, representing a dividend yield of 1.23% with a payout ratio of 14.9%. The quarterly dividend has been paid for 13 consecutive years, though its 5-year annualized dividend growth stands at 0.0%. The most recent ex-dividend date was September 2, 2026.

Wall Street analysts maintain 0 Strong Buy, 1 Buy, 2 Hold, and 1 Sell ratings on PAHC. The mean price target is $47.00, implying a 21.1% upside from the last close of $38.82. Analysts forecast current fiscal year ending June 30, 2027 EPS of $3.50 on revenue of $1.58B, and next fiscal year EPS of $3.85 on revenue of $1.63B. PAHC beat EPS estimates in each of the last 4 quarters, with its next earnings date scheduled for November 4, 2026.

This page is an AI-written research summary of Phibro Animal Health Corporation (PAHC). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: PAHC income statement, PAHC balance sheet, PAHC key metrics, PAHC analyst forecast, PAHC chart. See the PAHC stock overview for the latest quote and news.